Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.

doi:10.1038/s41397-024-00342-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.

The pharmacogenomics journal - 12 Jul 2024

Quintanilha Julia C F, Kelly William Kevin, Innocenti Federico

Abstract excerpt

Bevacizumab-induced hypertension poses a therapeutic challenge and identifying biomarkers for hypertension can enhance therapy safety. Lower plasma levels of VEGF-A, angiopoietin-2, and rs6770663 in KCNAB1 were previously associated with increased risk of bevacizumab-induced hypertension. This study investigated whether these factors independently contribute to grade 2-3 bevacizumab-induced hypertension risk in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiogenesis Inhibitors

Share to Angiopoietin-2

Share to Bevacizumab

Share to Hypertension

Share to Neoplasms

Share to Risk Factors

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 38992025
DOI: 10.1038/s41397-024-00342-1
PMCID: PMC11374128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.PMID 38992025Read ↗

Genetic markers of bevacizumab-induced hypertension.Semantic proximity Read ↗

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Semantic proximity Read ↗

PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.Semantic proximity Read ↗

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).Semantic proximity Read ↗

Genetic predisposition to bevacizumab-induced hypertension.Semantic proximity Read ↗

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Semantic proximity Read ↗

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Semantic proximity Read ↗

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Semantic proximity Read ↗

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.Semantic proximity Read ↗

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.Semantic proximity Read ↗

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.Semantic proximity Read ↗

Predictive value of loci in VEGF pathway genes in bevacizumab treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.